Thai Prophylactic HIV Vaccine Phase I Study

This study has been terminated.
(Vaccines safe but not immunogenic in 8 participants; trial closed to further recruitment by the protocol steering committee & DSMB.)
Sponsor:
Collaborator:
Thai Red Cross AIDS Research Centre
Information provided by (Responsible Party):
Kirby Institute
ClinicalTrials.gov Identifier:
NCT00333424
First received: June 1, 2006
Last updated: June 11, 2012
Last verified: June 2012

June 1, 2006
June 11, 2012
August 2007
July 2008   (final data collection date for primary outcome measure)
All safety data summarised & compared by randomly assigned vaccination group. Primary immunological outcome is mean difference in change in percent of IFN-y + CD4+ and/or CD8+ cells by intracellular cytokine staining (ICCS) from week 0 to 13. [ Time Frame: 13 weeks ] [ Designated as safety issue: Yes ]
The primary immunological measure will be the mean difference in change in percent of IFN-y + CD4+ and/or CD8+ cells by intracellular cytokine staining (ICCS) from baseline to week 13.
Complete list of historical versions of study NCT00333424 on ClinicalTrials.gov Archive Site
Proportion of patients with positive ICCS assay responses; peripheral blood mononuclear cell responses to HIV antigens; proportion of patients with positive ELIspot assay responses; anti-HIV Gag, Pol & Env antibodies. [ Time Frame: week 13 ] [ Designated as safety issue: No ]
Proportion of patients with positive ICCS assay responses; peripheral blood mononuclear cell responses to HIV antigens; proportion of patients with positive ELIspot assay responses; anti-HIV Gag, Pol & Env antibodies.
Not Provided
Not Provided
 
Thai Prophylactic HIV Vaccine Phase I Study
A Randomised, Placebo-Controlled, Double-Blind, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS-HIV-AE DNA Prime and rFPV-HIV-AE Boost HIV Vaccination Strategy

The development of a safe and effective vaccine for HIV is the subject of intensive world-wide research. Various approaches are being investigated in monkey models and humans. This is a randomized, double-blind trial to evaluate the safety and immunogenicity of a candidate preventative human immunodeficiency virus (HIV) vaccine strategy in 24 healthy adult Thai volunteers with no identifiable risk behaviour for HIV-1 infection. Volunteers will receive three "priming" vaccinations at weeks 0, 4 and 8 (pHIS-HIV-AE, a DNA vector delivering AE clade HIV-1 genes). This will be followed at week 12 by single "boost" vaccination (rFPV-HIV-AE, non-replicating, recombinant fowlpox virus vector delivering the same HIV-1 genes). Safety and immunological monitoring will continue to 52 weeks

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
HIV
Biological: pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine
6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
Placebo Comparator: Placebo
placebo containing diluent alone
Intervention: Biological: pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine
Hemachandra A, Puls RL, Sirivichayakul S, Kerr S, Thantiworasit P, Ubolyam S, Cooper DA, Emery S, Phanuphak P, Kelleher A, Ruxrungtham K. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin. 2010 Oct;6(10):835-40. Epub 2010 Oct 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
8
February 2009
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers, as judged by the screening physician based on medical history, physical examination and laboratory results
  • 18 - 55 years of age, inclusive
  • Laboratory blood values within clinically acceptable range
  • Women of reproductive potential must have a negative urine beta-human chorionic gonadotropin (B-HCG) pregnancy test at both the screening and baseline visits
  • Agreement to employ barrier contraception for 4 weeks preceding entry and for the whole duration of the study (52 weeks)
  • Agreement to undertake HIV testing and to receive results
  • Provision of written informed consent approved by the Institutional Ethics Committee (IEC).

Exclusion Criteria:

  • HIV positive
  • HBsAg or HCV positive
  • Identifiable risk behaviour for HIV infection, defined as any one of the following:

    • sexual partners of HIV positive people
    • individuals reporting unprotected intercourse with a partner of unknown HIV status, if that partner is reported to be at higher risk for HIV infection ("higher risk of HIV infection" is defined as individuals reporting unprotected anal intercourse (UAI), unprotected intercourse with sex workers and/or sharing injecting equipment within the 12 months preceding trial entry
    • men reporting any UAI with male partners of unknown status in the 12 months preceding entry to the study
    • individuals who in the 12 months preceding entry to the study have been diagnosed with a new sexually transmissible infection (STI) that may have been acquired through anal or vaginal intercourse (receptive or insertive)
    • individuals reporting sharing of injecting equipment in the last 12 months
  • Recipients of prior HIV candidate vaccines in a previous HIV vaccine trial (does not apply to volunteers who received placebo or adjuvant in such a trial)
  • Recipients of live attenuated vaccines within 60 days prior to entering the study. Whole killed, toxoid or sub-unit vaccines e.g. influenza, pneumococcus, tetanus, hepatitis B are not exclusionary when given at least 4 weeks prior to the scheduled experimental HIV vaccines
  • Known or suspected hypersensitivity to egg products or a known history of anaphylaxis or any other serious adverse reactions to any vaccinations
  • History of serious allergic reactions requiring hospitalisation or emergency medical care (e.g. Steven-Johnson's syndrome, bronchospasm or hypotension) to any substance
  • Clinically significant intercurrent illness or a history of clinically significant illness requiring immunomodulatory (including corticosteroids) or cytotoxic treatment (e.g. cancer) or any significant disease conditions that in the opinion of the Principal Investigator precludes the individual from participating in the study
  • Recipients of blood products or immunoglobulins within 6 months prior to entering the study
  • Recipients of experimental or investigational agents within 30 days prior to entering the study
  • Recreational and/or therapeutic drug-use that, in the opinion of the Principal Investigator, might compromise the volunteer's participation in any way
  • Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol
  • Pregnant or lactating women, or women planning to become pregnant during the trial.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Thailand
 
NCT00333424
NCHECR-AE1
Yes
Kirby Institute
Kirby Institute
Thai Red Cross AIDS Research Centre
Principal Investigator: Kiat Ruxrungtham, MD PhD HIV-NAT, Thai Red Cross AIDS Research Center
Kirby Institute
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP